J Korean Med Sci.  2009 Jan;24(Suppl 1):S115-S120. 10.3346/jkms.2009.24.S1.S115.

Associations between Oxidized LDL to LDL Ratio, HDL and Vascular Calcification in the Feet of Hemodialysis Patients

• An WS
• Kim SE
• Kim KH
• Bae HR
• Rha SH

• KMID: 1778150
• DOI: http://doi.org/10.3346/jkms.2009.24.S1.S115

Abstract

Cardiovascular mortality is associated with vascular calcification (VC) in hemodialysis (HD) patients. The present study was designed to find factors related with medial artery calcification on the plain radiography of feet by comparing C-reactive protein (CRP), plasminogen activator inhibitor type 1 (PAI-1) and lipid profile including oxidized low density lipoprotein (ox-LDL) and to elucidate associations among these factors in HD patients. Forty-eight HD patients were recruited for this study. VC in the feet was detected in 18 patients (37.5%) among total patients and 12 patients (85.7%) among diabetic patients. Diabetes, cardiovascular disease (CVD), pulse pressure, ox-LDL/LDL were higher and high density lipoprotein (HDL) was lower in patients with VC than in patients without VC. Negative associations were found between HDL and CRP, PAI-1. PAI-1 had positive association with ox-LDL/LDL. History of CVD was the only determinant of vascular calcification on the plain radiography of feet. Ox-LDL/LDL, HDL, CRP, and PAI-1 were closely related with one another in HD patients. History of CVD is the most important factor associated with the presence of VC and low HDL and relatively high oxidized LDL/LDL ratio may affect VC formation on the plain radiography in the feet of HD patients.

Keyword

Vascular Calcification; Oxidized Low Density Lipoprotein; High Density Lipoproteins; Hemodialysis

MeSH Terms

Aged
C-Reactive Protein/metabolism
Cardiovascular Diseases/blood/complications/diagnosis
Female
Foot
Humans
Kidney Failure, Chronic/blood/complications/diagnosis
Lipoproteins, HDL/*metabolism
Lipoproteins, LDL/*metabolism
Male
Middle Aged
Plasminogen Activator Inhibitor 1/metabolism
*Renal Dialysis
Risk Factors

Figure

• 

  Fig. 1 Standard radiograph of foot shows definite vascular calcifications on the course of dorsalis pedis artery. High density that outline the dorsalis pedis artery on the plain radiograph was shown as typical linear railroad-track form like angiography indicates vascular media calcification of dorsalis pedis artery (arrow).

• 

  Fig. 2 Correlation between CRP, PAI-1 and HDL in hemodialysis patients. CRP, C-reactive protein; PAI-1, plasminogen activator inhibitor 1; HDL, high density lipoprotein cholesterol.

Reference

1. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998. 32:5 Suppl 3. S112–S119.

2. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004. 164:659–663.

3. Blacher J, Guérin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999. 99:2434–2439.

4. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001. 38:938–942.

5. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000. 15:1014–1021.

6. Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Gonçalves M, Negrao AP. A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004. 19:1480–1488.

7. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996. 27:394–401.

8. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003. 18:1731–1740.

9. Coresh J, Longenecker JC, Miller ER, Young HJ, Klag MJ. Epidemiology of cardiovascular risk factors in chronic renal disease. J Am Soc Nephrol. 1998. 9:12 Suppl. S24–S30.

10. Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemodialysis: better nutrition as a partial explanation. ASAIO J. 2001. 47:74–81.

11. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003. 63:793–808.

12. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol. 2003. 14:1927–1939.

13. Libby P. Inflammation in atherosclerosis. Nature. 2002. 420:868–874.

14. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005. 352:1685–1695.

15. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002. 347:1557–1565.

16. Vaughan DE. PAI-1 and atherothrombosis. J Thromb Haemost. 2005. 3:1879–1883.

17. Honkanen E, Kauppila L, Wikström B, Rensma PL, Krzesinski JM, Aasarod K, Verbeke F, Jensen PB, Mattelaer P, Volck B. CORD study group. Abdominal aortic calcification in dialysis patients: results of the CORD study. Nephrol Dial Transplant. 2008. 23:4009–4015.

18. Toussaint ND, Kerr PG. Vascular calcification and arterial stiffness in chronic kidney disease: implications and management. Nephrology (Carlton). 2007. 12:500–509.

19. Porter CJ, Stavroulopoulos A, Roe SD, Pointon K, Cassidy MJ. Detection of coronary and peripheral artery calcification in patients with chronic kidney disease stages 3 and 4, with and without diabetes. Nephrol Dial Transplant. 2007. 22:3208–3213.

20. Takenaka T, Takahashi K, Kobayashi T, Oshima E, Iwasaki S, Suzuki H. Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in hemodialysis (HD) patients. Clin Nephrol. 2002. 58:33–37.

21. Cote C, Pibarot P, Despres JP, Mohty D, Cartier A, Arsenault BJ, Couture C, Mathieu P. Association between circulating oxidized low-density lipoprotein and fibrocalcific remodeling of the aortic valve in aortic stenosis. Heart. 2008. 94:1175–1180.

22. Kraśniak A, Drozdz M, Pasowicz M, Chmiel G, Michałek M, Szumilak D, Podolec P, Klimeczek P, Konieczyńska M, Wicher-Muniak E, Tracz W, Khoa TN, Souberbielle JC, Drueke TB, Sulowicz W. Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patients. Nephrol Dial Transplant. 2007. 22:515–521.

23. Galland F, Duvillard L, Petit JM, Lagrost L, Vaillant G, Brun JM, Gambert P, Vergés B. Effect of insulin treatment on plasma oxidized LDL/LDL-cholesterol ratio in type 2 diabetic patients. Diabetes Metab. 2006. 32:625–631.

24. Tinahones FJ, Gómez-Zumaquero JM, Garrido-Sánchez L, García-Fuentes E, Rojo-Martinez G, Esteva I, Ruiz de Adana MS, Cardona F, Soriguer F. Influence of age and sex on levels of anti-oxidized LDL antibodies and anti-LDL immune complexes in the general population. J Lipid Re. 2005. 46:452–457.

25. Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y. The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients. Kidney Int Suppl. 2003. 84:S128–S130.

26. Allison MA, Pavlinac P, Wright CM. The differential associations between HDL, non-HDL and total cholesterols and atherosclerotic calcium deposits in multiple vascular beds. Atherosclerosis. 2007. 194:e87–e94.

27. Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H, Fukiyama K. Significant association between the progression of coronary artery calcification and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis. 2001. 38:64–69.

28. Toikka JO, Ahotupa M, Viikari JS, Niinikoski H, Taskinen M, Irjala K, Hartiala JJ, Raitakari OT. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis. 1999. 147:133–138.

29. Segarra A, Chacón P, Martinez-Eyarre C, Argelaguer X, Vila J, Ruiz P, Fort J, Bartolomé J, Camps J, Moliner E, Pelegrí A, Marco F, Olmos A, Piera L. Circulating levels of plasminogen activator inhibitor type-1, tissue plasminogen activator, and thrombomodulin in hemodialysis patients: biochemical correlations and role as independent predictors of coronary artery stenosis. J Am Soc Nephrol. 2001. 12:1255–1263.

30. Caló LA, Naso A, Carraro G, Wratten ML, Pagnin E, Bertipaglia L, Rebeschini M, Davis PA, Piccoli A, Cascone C. Effect of haemodiafiltration with online regeneration of ultrafiltrate on oxidative stress in dialysis patients. Nephrol Dial Transplant. 2007. 22:1413–1419.

31. Asmus H-G, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, Neumayer HH, Raggi P, Bommer J. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005. 20:1653–1661.